Amgen pursuing Kyprolis label expansion on ASPIRE data
This article was originally published in Scrip
Executive Summary
Amgen reported positive interim results from the first of two highly anticipated Phase III clinical trials for the Kyprolis (carfilzomib) in multiple myeloma on 4 August and the biotechnology giant's stock closed 2.5% higher as investors breathed a sigh of relief.